ReviewPostgraduate medical journal2006
Interstitial lung disease: progress and problems.
Review in Postgraduate medical journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06141603 (Comparison of Upper and Lower Limb Maximal Exercise Capacities, Muscle Oxygenation and Energy Consumption During Tests in Patients With Interstitial Lung Disease), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Upper and Lower Limb Maximal Exercise Capacities, Muscle Oxygenation and Energy Consumption During Tests in Patients With Interstitial Lung Disease
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Cryptotanshinone is a candidate therapeutic agent for interstitial lung disease associated with a BRICHOS-domain mutation ofiScience · 2023Article
- Usefulness of a new parameter in functional assessment in patients with idiopathic pulmonary fibrosis: desaturation - distance ratio from the six-minute walk test.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19.Prostaglandins, leukotrienes, and essential fatty acids · 2022Article
- Deficiency of Sphingosine-1-Phosphate Receptor 2 (S1PBiomolecules & therapeutics · 2019Article
- Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.Clinical rheumatology · 2018Observational
- Determination of disease phenotypes and pathogenic variants from exome sequence data in the CAGI 4 gene panel challenge.Human mutation · 2017Article
- Targeting sphingosine-1-phosphate signaling in lung diseases.Pharmacology & therapeutics · 2016Review
- Cartography of Pathway Signal Perturbations Identifies Distinct Molecular Pathomechanisms in Malignant and Chronic Lung Diseases.Frontiers in genetics · 2016Article
- Article
- Grating-based X-ray Dark-field Computed Tomography of Living Mice.EBioMedicine · 2015Article
- Bax deficiency extends the survival of Ku70 knockout mice that develop lung and heart diseases.Cell death & disease · 2015Article
- Computer-aided detection of early interstitial lung diseases using low-dose CT images.Physics in medicine and biology · 2011Article
- BAL fluid cells in newly diagnosed pulmonary sarcoidosis with different clinical activity.Upsala journal of medical sciences · 2009Article
- Ultrasound in the evaluation of interstitial pneumonia.Journal of ultrasound · 2008Article
- Long COVID Mimicking Interstitial Lung Disease: A Case Series.Current health sciences journalArticle
- Interspecies Organogenesis for Human Transplantation.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease involves all areas of medicine as it often occurs in patients with comorbidities or as a consequence of systemic diseases and their treatment. Typically the physician is faced with a breathless patient, a diffusely abnormal chest radiograph, and a wide differential diagnosis. Progress has been made in using high resolution computed tomography as the key investigation in characterising the pattern and extent of the disease. Bronchoalveolar lavage is particularly important in excluding infection as a cause of diffuse lung infiltrates. Surgical lung biopsies have led to a new classification system for the range of histopathological patterns of disease that were previously known by the collective term cryptogenic fibrosing alveolitis. Problems persist in deciding when a surgical lung biopsy is clinically justified, in understanding the pathogenesis of these diseases, and in finding more effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.